Drug General Information (ID: DDI02GMBNS)
Drug Name			Albendazole		Drug Info		Omacetaxine mepesuccinate		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiprotozoal Agents				Antineoplastics
Structure

Mechanism of Albendazole-Omacetaxine mepesuccinate Interaction (Severity Level: Moderate)
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Albendazole				Omacetaxine mepesuccinate
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Albendazole and Omacetaxine mepesuccinate

Recommended Action
Management		Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms such as fever, chills, shortness of breath, fatigue, and any unusual bleeding or bruising.

References
1	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.